Trial Profile
To evaluate the effectiveness of Octreotide as an alternative therapy to treat Hyperinsulinemic Hypoglycemia in small-for-gestational-age neonates
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2016
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Hypoglycaemia
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2016 New trial record